Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
24.02B
Market cap24.02B
Price-Earnings ratio
63.37
Price-Earnings ratio63.37
Dividend yield
—
Dividend yield—
Average volume
1.42M
Average volume1.42M
High today
—
High today—
Low today
—
Low today—
Open price
$118.77
Open price$118.77
Volume
0.00
Volume0.00
52 Week high
$132.60
52 Week high$132.60
52 Week low
$89.25
52 Week low$89.25

Stock Snapshot

With a market cap of 24.02B, Incyte(INCY) trades at $117.00. The stock has a price-to-earnings ratio of 63.37.

On 2026-11-19, Incyte(INCY) shares started trading at $118.77, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.42M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $132.60 and a low of $89.25.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $132.60 and a low of $89.25.

INCY News

Barchart 1h
What Are Wall Street Analysts' Target Price for Incyte Stock? - Barchart.com

...

What Are Wall Street Analysts' Target Price for Incyte Stock? - Barchart.com
Simply Wall St 1h
Don't Ignore The Insider Selling In Incyte

Some Incyte Corporation ( ) shareholders may be a little concerned to see that insider Lee Heeson recently sold a substantial US$1.3m worth of stock at a price...

Don't Ignore The Insider Selling In Incyte
TipRanks 2d
Buy Rating Reiterated as Povorcitinib Gains First European Approval and U.S. Launch Prospects Strengthen; Price Target Unchanged at $152

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Incyte, with a price target of $152.00. John Newman has given his Buy...

Analyst ratings

52%

of 29 ratings
Buy
44.8%
Hold
51.7%
Sell
3.4%

More INCY News

TipRanks 3d
Incyte’s Povofortay approved in Europe in hidradenitis suppurativa

The company states: “Incyte (INCY) announced that the European Commission has approved Povofortay, or povorcitinib, 45 mg and 75 mg for the treatment of eligibl...

TipRanks 6d
Incyte Discontinues Planned Phase 3 Ovarian Cancer Study

Incyte ( (INCY) ) has shared an announcement. Incyte Corporation is developing INCB123667, a selective CDK2 inhibitor, for ovarian cancer. The company decided...

TipRanks 6d
Incyte will not proceed with planned Phase 3 MAESTRA-3 study of INCB123667

Incyte (INCY) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the company’s selective CDK2 inhibitor, in combination...

Simply Wall St 7d
Incyte Expands Beyond JAKAFI, Is The Stock Still Cheap?

Incyte (INCY) just paired its push beyond JAKAFI with fresh news in colorectal cancer. A new phase II collaboration with Natera centers on INCA33890 and MRD-gui...

Incyte Expands Beyond JAKAFI, Is The Stock Still Cheap?

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.